Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection (Oct, 10.1007/s40265-022-01797-x, 2022)

Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection (Oct, 10.1007/s40265-022-01797-x, 2022) Article

Full Text via DOI: 10.1007/s40265-022-01805-0 Web of Science: 000879675000001

Cited authors

Khanna S, Assi M, Lee C, Yoho D, Louie T, Knapple W, Aguilar H, Garcia-Diaz J, Wang GP, Berry SM, Marion J, Su X, Braun T, Bancke L, Feuerstadt P

Authors

Garcia-Diaz, Julia, MD

Publication date

2022

Published in

Drugs Journal

International Standard Serial Number (ISSN)

0012-6667

Number of pages

1